Erasca Posts $51.3M Q3 Loss as $947.8M Cash Pile Funds RAS Pipeline
ERAS has more than doubled off its 52-week low of $2.34.
Summary
Erasca's Q3 net loss widened to $51.3M, or $0.15 per share, from $30.6M, or $0.11 per share, a year earlier, as spending on the RAS pipeline ramps up. The balance sheet is the story: cash, equivalents and marketable securities stood at $947.8M on September 30, up from $341.8M at December 31, 2025, which the company says covers its near-term milestones. That cushion is large relative to the company's size, so dilution risk near term is limited. Pipeline timing is the swing factor — preliminary ERAS-4001 data are expected in H2 2026, with ERAS-0015 data in H1 2027. The filing also discloses a new Revolution Medicines patent matter, a legal overhang worth tracking alongside the clinical readouts.
At the time of this announcement, ERAS was trading at $15.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $2.34 to $24.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.